{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:26:39Z","timestamp":1761056799546},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,5,3]],"date-time":"2002-05-03T00:00:00Z","timestamp":1020384000000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the safety of a licensed anthrax vaccine given to nearly 400\u2009000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Anthrax Vaccine Expert Committee (AVEC), a civilian panel of private\u2010sector physicians and other scientists, reviewed 602 VAERS reports using a Delphic approach (structured expert consensus) to assess the causal relationship between vaccination and the reported AEs and sought to identify unexpected patterns in the occurrence of medically important events. Reports were entered into a database and used to profile AEs with respect to person, type\/location, relative frequency, severity\/impact, concomitant illness or receipt of other drugs or vaccines, and vaccine lot.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nearly half the reports noted a local injection\u2010site AE, with more than one\u2010third of these involving a moderate to large degree of inflammation. Six events qualified as serious AEs (SAEs), and all were judged to be certain consequences of vaccination. Three\u2010quarters of the reports cited a systemic AE (most common: flu\u2010like symptoms, malaise, rash, arthralgia, headache), but only six individual medically important events were judged possibly or probably due to vaccine (aggravation of spondyloarthropathy (2), anaphylactoid reaction, arthritis (2), bronchiolitis obliterans organizing pneumonia)<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Since some cases of local inflammation involved distal paresthesia, AVEC recommends giving subcutaneous injections of AVA over the inferior deltoid instead of the triceps to avoid compression injury to the ulnar nerve. At this time, ongoing evaluation of VAERS reports does not suggest a high frequency or unusual pattern of serious or other medically important AEs. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.712","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:27:00Z","timestamp":1030318020000},"page":"189-202","source":"Crossref","is-referenced-by-count":47,"title":["Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)"],"prefix":"10.1002","volume":"11","author":[{"given":"John L.","family":"Sever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan I.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold D.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry M.","family":"Lyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,3]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"69","article-title":"Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management\u2014United States, 1998","volume":"48","year":"1999","journal-title":"Morb Mort Wkly Rep"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican1296-60"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.1997.03550050080037","article-title":"Iraq's biological weapons. The past as future?","volume":"278","author":"Zilinskas RA","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.22.2104"},{"key":"e_1_2_1_8_2","volume-title":"Defense Almanac","author":"Department of Defense","year":"2000"},{"key":"e_1_2_1_9_2","first-page":"629","volume-title":"Vaccines","author":"Brachman PS","year":"1999"},{"key":"e_1_2_1_10_2","first-page":"51002","article-title":"Food and Drug Administration. Biologic products; bacterial vaccines and toxoids; implementation of efficacy review","volume":"50","year":"1985","journal-title":"Fed Reg"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.52.2.454-458.1986"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.52.2.509-512.1986"},{"key":"e_1_2_1_13_2","unstructured":"Congressional Testimony before Subcommittee on National Security Veterans Affairs and International Relations. (29 April1999) (testimony of M. Nass)."},{"key":"e_1_2_1_14_2","unstructured":"Congressional Testimony before Subcommittee on National Security Veterans Affairs and International Relations. (29 April1999) (testimony of K. C. Zoon)."},{"key":"e_1_2_1_15_2","unstructured":"Congressional Testimony before Subcommittee on National Security Veteran Affairs and International Relations (21 July1999) (testimony of S. S. Ellenberg)."},{"key":"e_1_2_1_16_2","unstructured":"Anthrax Vaccine Immunization Program (AVIP).Safety Review of Anthrax Vaccine 5 November 2000. Available at:http:\/\/www.anthrax.osd.mil\/Site_Files\/articles\/INDEXclinical\/safety_reviews.htm. [November2000]."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.52.4.632"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-5-594"},{"key":"e_1_2_1_19_2","first-page":"341","article-title":"Centers for Disease Control and Prevention. Surveillance for adverse events associated with anthrax vaccination\u2014U.S. Department of Defense, 1998\u20132000","volume":"49","year":"2000","journal-title":"Morb Mort Wkly Rep"},{"key":"e_1_2_1_20_2","first-page":"730","article-title":"Centers for Disease Control and Prevention. Vaccine adverse event reporting system\u2014United States","volume":"39","year":"1990","journal-title":"Morb Mort Wkly Rep"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00132-2"},{"key":"e_1_2_1_22_2","first-page":"10","article-title":"The complicated task of monitoring vaccine safety","volume":"112","author":"Ellenberg SS","year":"1997","journal-title":"Pub Health Rep"},{"key":"e_1_2_1_23_2","unstructured":"Department of Defense.Policy for Reporting Adverse Events Associated with the Anthrax Vaccine. Available at:http:\/\/www.anthrax.osd.mil\/Site_Files\/Policies\/Policy_VAERS_files\/POLICY_VAERS.htm. [November2000]."},{"key":"e_1_2_1_24_2","first-page":"178","article-title":"Advisory Committee on Causality Assessment. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee","volume":"78","author":"Collet J\u2010P","year":"2000","journal-title":"Bull WHO"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7001.376"},{"key":"e_1_2_1_26_2","unstructured":"Department of Defense.Clinical Guidelines for Managing Adverse Events after Vaccination. February 2001 edition. Available at:http:\/\/www.anthrax.osd.mil\/Site_Files\/articles\/INDEXclinical\/clinical_guidelines_files\/clinical_practice_guidelines.htm. [March2001]."},{"key":"e_1_2_1_27_2","volume-title":"Coding Symbols for Thesaurus of Adverse Reaction Terms","author":"Food and Drug Administration","year":"1995"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00014-6"},{"key":"e_1_2_1_29_2","volume-title":"Army Anthrax Vaccine Implementation Plan, Annex C: Medical Consideration\/Guidance","author":"Department of Defense","year":"2001"},{"key":"e_1_2_1_30_2","volume-title":"Secretary of the Navy Instruction 6230.4: Department of the Navy (DON) Anthrax Vaccination Implementation Program (AVIP), Annex A: Medical Considerations and Guidance","author":"Department of Defense","year":"2001"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.981"},{"key":"e_1_2_1_32_2","unstructured":"Food and Drug Administration.Voluntary Recall of Anthrax Vaccine Adsorbed. Available at:http:\/\/www.fda.gov\/cber\/fprecalls\/anthbio083000.htm. [December2000]."},{"key":"e_1_2_1_33_2","article-title":"Anthrax vaccine: immunogenicity and safety of a dose\u2010reduction, route\u2010change comparison study in humans","author":"Pittman PR","year":"2001","journal-title":"Vaccine"},{"key":"e_1_2_1_34_2","first-page":"577","article-title":"Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine\u2014United States, 1998\u20131999","volume":"48","year":"1999","journal-title":"Morb Mort Wkly Rep"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102223440804"},{"key":"e_1_2_1_36_2","first-page":"1007","article-title":"Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation","volume":"48","year":"1999","journal-title":"Morb Mort Wkly Rep"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T07:56:40Z","timestamp":1700294200000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1002\/pds.712"],"URL":"https:\/\/doi.org\/10.1002\/pds.712","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}